Covington & Burling LLP | Biographies | Peter A. Laveran-Stiebar

Peter Laveran is a corporate partner resident in Covington's London office. Mr. Laveran has a broad-based corporate and securities transactional practice, focusing on cross-border mergers and acquisitions, venture capital and private equity transactions, US securities offerings and other corporate finance matters. He advises US and foreign private issuers in connection with their US and international capital raising activities (including AIM IPOs, Rule 144A, Regulation S and registered offerings), debt and equity tender offers and their US reporting obligations. His M&A experience includes advising a variety of US and international companies and private equity firms on public and private acquisitions and divestitures and joint ventures. Mr. Laveran has also represented venture capital and private equity groups on the formation and management of investment funds and in their investments in early and later stage companies.

Representative Matters

Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd.’s platform technology for monoclonal antibody discovery.
Represented HealthpointCapital Partners as a selling shareholder in Alphatec Holdings, Inc.'s underwritten public offering of 18.4 million shares of common stock for total proceeds to HealthpointCapital and Alphatec of approximately $85 million.
Represented Trinity Equity Investments I, LLC in its investment in, and recapitalization of, Ricerca Biosciences, LLC, which was completed in connection with Ricerca’s acquisition of the Discovery and Preclinical business of MDS Pharma Services.
Represented funds managed by HealthpointCapital, LLC in the sale of their controlling interest in Scient'x Groupe SAS to Alphatec Holdings, Inc.
Represented Scient'x S.A. in connection with a multi-jurisdictional secured loan by Oxford Finance Corporation, a life sciences venture lender, to Scient'x USA, Inc. secured by the stock and assets of Scient'x S.A. and subsidiaries in France, Italy, Australia and the United Kingdom.
Represented Piper Jaffray Ltd., the sole financial advisor, sponsor, underwriter and broker to Vernalis plc, the London main market listed development stage pharmaceutical company, in its placing and open offer raising £24 million.
Represented Dr. George Jokhtaberidze in connection with various transactions and shareholder arrangements relating to his 51% ownership interest in leading Georgian telecommunications company Magticom Ltd.
Represented International Specialty Products, Inc. on the sale of its UK-based hydrocolloids ingredients business to FMC Corporation.
Represented Collins Stewart Europe Limited, as Nomad and broker, to the AIM IPO of HipCricket, Inc., a US-based mobile marketing company, and the proposed AIM IPO of a US-based semi-conductor company.
Represented HealthpointCapital Partners in its €71 million acquisition by way of private purchase and public tender offer of Ideal Medical Products, S.A., a French company listed on Euronext Paris.